Therapeutic effect of recombinant human growth hormone on children with growth hormone deficiency and different pituitary developmental conditions: a prospective study.
10.7499/j.issn.1008-8830.2302018
- Author:
Xiu-Fang WEI
1
;
Yue-Ying ZHANG
;
Zhi-Ping YAN
1
;
Jing AN
Author Information
1. Department of Pediatrics, Xuchang Maternity and Child Health Hospital, Xuchang, Henan 461000, China.
- Publication Type:Journal Article
- Keywords:
Child;
Growth hormone deficiency;
Insulin-like growth factor binding protein-3;
Insulin-like growth factor-1;
Pituitary development;
Recombinant human growth hormone
- MeSH:
Child;
Female;
Humans;
Pregnancy;
Body Height;
Human Growth Hormone/therapeutic use*;
Hyperplasia;
Insulin-Like Growth Factor Binding Protein 3;
Insulin-Like Growth Factor I;
Prospective Studies;
Pituitary Gland/pathology*;
Recombinant Proteins/therapeutic use*
- From:
Chinese Journal of Contemporary Pediatrics
2023;25(8):800-804
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVES:To investigate the therapeutic effect of recombinant human growth hormone (rhGH) on children with growth hormone deficiency (GHD) and different pituitary developmental conditions.
METHODS:A prospective study was performed on 90 children with GHD who were admitted to Xuchang Maternity and Child Health Hospital from June 2020 to December 2021. According to pituitary height on the median sagittal plane, they were divided into three groups: pituitary dysplasia group (n=45), normal pituitary group (n=31), and enlarged pituitary growth group (n=14). The changes in body height, growth velocity, height standard deviation score and serum levels of insulin-like growth factor binding protein-3 (IGFBP-3) and insulin-like growth factor-1 (IGF-1) were examined after treatment in the above three groups, and the differences of the above indices before and after treatment were compared among the three groups.
RESULTS:After treatment, all three groups had significant increases in body height, growth velocity, height standard deviation score, and the serum levels of IGFBP-3 and IGF-1 (P<0.05). Compared with the normal pituitary group, the pituitary dysplasia group and the enlarged pituitary growth group had significantly higher values in terms of the differences in body height, growth velocity, height standard deviation score, IGF-1, and IGFBP-3 before and after treatment (P<0.05). There was no significant difference in the incidence rate of adverse reactions among the three groups (P>0.05).
CONCLUSIONS:In GHD children with different pituitary developmental conditions, rhGH can promote bone growth and increase body height, especially in children with pituitary dysplasia and pituitary hyperplasia, with good safety.
